Study of Non Inferiority Bi-Profenid® 200mg Versus Bi-Profenid® 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)

NCT00810121 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

409

Enrollment

INDUSTRY

Sponsor class

Conditions

Pain

Interventions

DRUG: ketoprofen 100 mg
DRUG: ketoprofen

Sponsor

Sanofi